Clinical implementation of testing and PARPi as monotherapy Summit - Dr. Neal Shore Clinicians & Genetics - Dr. Neal Shore | #activesurveillance #aspi2020
Insurance & Genetics - Dr. Neal Shore | #activesurveillance #aspi2020 Episode 218: Breaking Barriers in Urologic Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Neal Shore of Atlantic Urology Clinics, Myrtle Dr. Neal D. Shore discusses and fields questions on maximizing health during and after prostate cancer treatment. Dr. Shore is
The Precision Prostate Cancer mdxhealth Pathway Helping you modernize prostate cancer evaluation and management for more Phase 3 trial results suggest potential new treatment approach for prostate cancer
Dr. Neal Shore on Lack of Corticosteroid-Associated Adverse Events with Prednisone Plus Abiraterone Dr. Neal Shore, MD, FACS, stands in for Deepak A. Kapoor, MD, at the 28th International Prostate Cancer Update, summarizing
This week Jonathan is joined by Neal Shore, Medical Director at Carolina Urologic Research Center and Chief Medical Officer of Biomarkers in Prostate Cancer: A Guide to to Personalized Care Featuring Dr. Neal Shore
Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE A discussion with Neal D. Shore, MD, on Castrateresistant Prostate Cancer and Bone Metastases
Moderator Raoul S. Concepcion, MD, introduces the panel a unique panel discussion that features peer-to-peer expert exchange, Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations Dr. Neal Shore Discusses ODM-201 in CRPC
Dr. Shore, Director, Carolina Urologic Research Center, offers his opinion on whether or not BRCA1 and BRCA2 genetic testing ProstateCancer #AdvancedProstateCancer #CancerTreatment #MedicalPodcast #DrGeo #DrNealShore #ProstateHealth Neal Shore - The START Center for Cancer Research | LinkedIn
Clinical research and the ENACT trial with Neal Shore He serves as the Medical Director for the Carolina Urologic Research Center. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on
Visit for more information. Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer
Join us as Neal Shore, MD, FACS presents Biomarkers in Prostate Cancer Care: A Guide to Personalized Care. Dr. Shore GeneticPrivacy #HealthPolicy In this set of shorts, Dr. Neal Shore explains why germline genetic testing matters for people with
Dr. Neal D. Shore on the Approval of Radium-223 Maximizing Health Before and After Prostate Cancer Treatment.wmv
Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients ASCO 2017: Following the practice changing results from STAMPEDE Dr. Neal Shore On The Androgen Receptor
Dr. Shore Discusses First Commercial Dose of New Prostate Cancer Treatment on local TV Dr. Shore, MD, Director, Carolina Urologic Research Center, describes where chemotherapy fits into treatment for prostate cancer.
Dr. Neal Shore, Director, CPI, Carolina Urologic Research Center, was a featured speaker at the 2010 Summit to End Prostate Treatment Talk | Clinical Trials | What happens after I sign the consent form?
Featuring perspectives from Dr Neal D Shore and Dr Mary-Ellen Taplin, including the following topics: • Introduction (0:00) • Key ClinicianEducation #ProstateCancer In this set of shorts, Dr. Neal Shore explains why germline genetic testing matters for people The Evolution of Understanding the USPSTF
Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment Peer Exchange: Introduction to Urologists in Cancer Care Panel Discussion
Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer Precision Prostate Cancer Pathway, Dr Shore
From ASCO 2011 -- A discussion with Neal D. Shore, MD, Director and CPI at the Carolina Urologic Research Center, Myrtle Dr. Neal Shore is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Neal Shore (0000-0001-5767-0548) - ORCID Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses
Host: Neal Shore, MD, FACS Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Authors: Neal D. Shore, M.D., Fred Saad, M.D., Michael S.
LISTEN: Preserving Independent Urology: LUGPA's First Decade Immunotherapy for Advanced Prostate Cancer with Neal Shore, MD- EP 103 Treatment Talk | Clinical Trials | Do I Have to Go to an Academic Hospital?
Neal D Shore, MD | Urology | Grand Strand Health Dr. Neal Shore discusses What To Expect after the Prostate Cryotherapy
Dr. Shore, MD, Director, Carolina Urologic Research Center, details how CHAARTED and STAMPEDE influenced his treatment of Wilfehrt; Matthew Harmon; Nadeem A. Sheikh; Neal D. Shore et al. Show more detail.
Neal Shore, MD, FACS | Atlantic Urology Clinics Prostate Cancer | Inside the Issue: Exploring the Current and Future Management of High-Risk, Hor
For more resources and information regarding anticancer targeted therapies: Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Non Treatment Talk | Clinical Trials | What are the key questions I should ask?
GermlineTesting #PrecisionMedicine #ProstateCancer In this set of shorts, Dr. Neal Shore explains why germline genetic testing Neal D. Shore, MD, and E. David Crawford, MD, discuss Dr. Shore's recent MedReview article on the ways in which the Large Oral Relugolix for Androgen-Deprivation Therapy in Advanced
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Under the direction of Myrtle Beach urologist Dr. Neal Shore, Hoffman has been involved in a trial for a new drug called
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor Neal D. Shore, MD
Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA) and Professor Nicholas James (Institute GeneticTesting #HealthEquity In this set of shorts, Dr. Neal Shore explains why germline genetic testing matters for people with Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the
September was Prostate Cancer Awareness Month, but it is important to focus on Prostate Cancer every month of the year. PARP inhibitor monotherapy
Join Dr. Peter H. O'Donnell, Dr. Neal Shore, and patient advocates to bust up some of the myths of being on a clinical trial as Dr. Shore, Director, Carolina Urologic Research Center, explains how an AR-V7 commercial test will affect initial and subsequent
In this GU CONNECT programme, brought to you by Dr Neal Shore, you'll follow a patient through their metastatic Dr. Neal Shore Discusses the Enzalutamide (MDV3100) AFFIRM Trial
Dr. Shore, MD, Director, Carolina Urologic Research Center, on which metastatic castration-resistant prostate cancer patients I host Dr. Neal Shore, a urologic oncologist who became heavily involved in GU oncology research including trials that
Dr. Shore on the Development of Immunotherapies for Prostate Cancer New drug gives hope to prostate cancer patients Dr. Neal Shore on Treatment of Elderly Patients With mCRPC
Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate Dr. Neal Shore 10 02 19 Prostate Cancer
As an award-winning urologist, Dr. Shore has conducted more than 350 clinical trials… · Experience: The START Center for Cancer Research · Education: Duke Neal D. Shore, MD, FACS - The START Center for Cancer Research Testing Is Underused - Dr. Neal Shore | #activesurveillance #aspi2020
Dr. Neal Shore discusses The Benefit of Cryotherapy With an Enlarged Prostate Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU
Dr. Shore on Patient Considerations Following Treatment With Radium-223 Dr. Neal Shore discusses what is salvage prostate cryotherapy?
In this animated video brought to you by Dr Neal Shore, you'll follow a patient through their metastatic castration-resistant prostate Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test Universal Testing Case - Dr. Neal Shore | #activesurveillance #aspi2020
Dr. Neal Shore, director of the Carolina Urologic Research Center and Board Certified Urologist with Coastal Carolina Radiation Dr. Neal Shore talks about the role of the androgen receptor in prostate cancer with Prostatepedia (
Neal Shore, MD, FACS – Bladder Cancer Advocacy Network Treatment Talk | Clinical Trials | Health Equity and Clinical Trials Dr. Neal Shore discusses the side effects of primary prostate cryotherapy
Neal D. Shore, MD, FACS Neal D. Shore, MD - Phone (843) 449-1010 - Specialty Urology - Gender Male - Languages English - Please call if you are a self-pay patient. Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York
Neal D Shore , Fred Saad , Michael S Cookson , Daniel J George , Daniel R Saltzstein , Ronald Tutrone , Hideyuki Akaza